{"id":15993,"date":"2025-01-20T09:10:01","date_gmt":"2025-01-20T08:10:01","guid":{"rendered":"https:\/\/www.adas.org.rs\/?p=15993"},"modified":"2025-11-19T09:43:07","modified_gmt":"2025-11-19T08:43:07","slug":"wada-se-nece-zaliti-na-odluku-o-zabrani-za-igu-svjontek","status":"publish","type":"post","link":"https:\/\/www.adas.org.rs\/en\/iz_medija\/2025\/01\/20\/wada-se-nece-zaliti-na-odluku-o-zabrani-za-igu-svjontek\/","title":{"rendered":"WADA will not appeal against Swiatek ban decision"},"content":{"rendered":"<p><\/p>\n<p>The World Anti-Doping Agency will not appeal against the ban given to Poland&#8217;s Iga Swiatek.<\/p>\n<p>The five-time major winner tested positive for heart medication trimetazidine (TMZ) in an out-of-competition sample in August 2024.<\/p>\n<p>The International Tennis Integrity Agency (ITIA) accepted the test result was caused by contamination and the world number two served a one-month suspension, which ended on 4 December.<\/p>\n<p>&#8220;I&#8217;m just satisfied I can get a closure, kind of, and I can just move on and finish this whole process,&#8221; said Swiatek after she beat Eva Lys to reach the quarter-finals of the Australian Open.<\/p>\n<p>https:\/\/www.bbc.com\/sport\/tennis\/articles\/cn57xwvyl1xo<\/p>","protected":false},"excerpt":{"rendered":"<p>The World Anti-Doping Agency will not appeal against the ban given to Poland&#8217;s Iga Swiatek. The five-time major winner tested positive for heart medication trimetazidine (TMZ) in an out-of-competition sample in August 2024. The International Tennis Integrity Agency (ITIA) accepted the test result was caused by contamination and the world number two served a one-month <a href=\"https:\/\/www.adas.org.rs\/en\/iz_medija\/2025\/01\/20\/wada-se-nece-zaliti-na-odluku-o-zabrani-za-igu-svjontek\/\" class=\"more-link\">&#8230;<span class=\"screen-reader-text\">  WADA will not appeal against Swiatek ban decision<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-15993","post","type-post","status-publish","format-standard","hentry","category-iz_medija"],"_links":{"self":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts\/15993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/comments?post=15993"}],"version-history":[{"count":3,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts\/15993\/revisions"}],"predecessor-version":[{"id":16824,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts\/15993\/revisions\/16824"}],"wp:attachment":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/media?parent=15993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/categories?post=15993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/tags?post=15993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}